Navigation Links
Neurocrine Biosciences Reports Third Quarter 2013 Results
Date:10/29/2013

ated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's R & D pipeline include risk that elagolix, the company's lead clinical program, will fail to demonstrate that elagolix is safe and effective; risk that elagolix Phase III clinical trials will be delayed for regulatory or other reasons; and risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. Similarly, the Company faces risk that the clinical studies for NBI-98854, the company's VMAT2 inhibitor candidate, will fail to demonstrate that NBI-98854 is safe and effective; risk that NBI-98854 Phase II clinical trials will be delayed for regulatory or other reasons; and risk that NBI-98854 will not proceed to later stage clinical trials. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that m
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2013 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
5. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Neurocrine Biosciences Reports Third Quarter 2012 Results
7. Neurocrine Biosciences Reports Second Quarter 2012 Results
8. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
9. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- The UPMC Center for Health Security today announced ... Leaders in Biosecurity Initiative (ELBI). As part of our ... biosecurity, UPMC has selected 28 US and international emerging ... including biological science, medicine, policy, the military, think tanks ... vision and support of the Defense Threat Reduction Agency ...
(Date:3/4/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") ... collaborative research program with Emerald Logic, a ... Evolution Technology (FACET), Emerald Logic analyzed Resverlogix,s ... from each of 798 patients who participated ... ASSERT, SUSTAIN and ASSURE. The objective of ...
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... VANCOUVER, British Columbia and SAN DIEGO, May 13 ... molecular,diagnostic tests for medical applications, announced today that ... Scientific Advisory Board. Dr.,Valcke has more than 20 ... including design, validation, manufacturing and clinical,development for medical ...
... WEINHEIM, Germany, May 13 Caviar has become ... in view of the over fished,sturgeon populations in ... satisfied,with sustainable aquaculture. United Food Technologies AG (UFT) ... in know-how in this sector.,This week, the company ...
... Conference call scheduled today at 8:00 a.m. Pacific Time, ... SGXP ) today announced its financial results for the ... 31, 2008, the Company posted,total revenues of $17.0 million ... million of revenue earned in the quarter that was,attributable ...
Cached Biology Technology:Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board 2Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board 3Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant 2SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 2SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 3SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 4SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 5SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 6SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 7SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 8
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/19/2015)... DUBLIN , Feb .19, 2015 Research ... announced the addition of the "Military Electro-Optical ... by Sensor Technology, by Platform - Forecast to ... The military electro-optical/infrared systems market is expected ... a CAGR of 7.71%. This report ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... a study has compared water quality trends in forested streams ... or land cover changes. The study, which draws on ... states and Puerto Rico, underscores the value of long-term data ... in streams and rivers. It is published in the current ...
... sick with colon cancer, received a blood transfusion. Then, unexpectedly, ... on her case, the French medical journal Revue D,Hmatologie identified ... it turns out, Mrs. Vel had developed a potent antibody ... of most people in the worldbut not found on her ...
... Philanthropist, businessman and community leader John Moores has given ... fund the development of a new field test for ... tens of millions of people in Africa, Latin America ... John,s generosity and foresight," said Michael A. Marletta, president ...
Cached Biology News:Study explores long-term water quality trends in near-pristine streams 2Baffling blood problem explained 2Baffling blood problem explained 3John Moores gives $2 million to Scripps Research to develop river blindness field test 2
... wall plates have low background fluorescence, ... Not treated (or medium binding) polystyrene ... binds biomolecules through passive interactions,• ... of large molecules, such as antibodies, ...
... washer 100-240 V, is used for washing ... V-bottom wells. The immunowash microplate washer has ... to an accuracy of 0.1 mm for ... It can store up to 75 wash ...
... The Model 1575 immunowash microplate washer, 100-240 ... that have flat-, U-, or V-bottom wells. ... vertical needle positions to an accuracy of ... and overflow washing. It can store up ...
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
Biology Products: